Table 3.
Acceptability of hypothetical HIV vaccines and impact of vaccine attributes on acceptability (n = 27).
| Vaccine atributes | ||||||||
|---|---|---|---|---|---|---|---|---|
| Hypothetical HIV vaccine numbera | HIV vaccine acceptability (mean) | Efficacy (%) | Side-effects | Duration of protection | Protection (cross-clade) | Cost ($) | Doses | Route |
| 1 | 85.2 | 99 | None | 10 years | One type | 0 | 1 | Injection |
| 2 | 72.2 | 99 | Minor | 10 years | Multiple types | 250 | 4 | Injection |
| 3 | 70.4 | 99 | None | 1 year | Multiple types | 250 | 1 | Oral |
| 4 | 57.4 | 99 | Minor | 1 year | One type | 0 | 4 | Oral |
| 5 | 30.6 | 50 | None | 1 year | Multiple types | 0 | 4 | Injection |
| 6 | 23.2 | 50 | Minor | 10 years | Multiple types | 0 | 1 | Oral |
| 7 | 18.5 | 50 | None | 10 years | One type | 250 | 4 | Oral |
| 8 | 7.4 | 50 | Minor | 1 year | One type | 250 | 1 | Injection |
| Mean Impact Scoreb | 51.4* | 11.1* | 8.3* | 6.9 | 6.9 | 1.9 | −6.5 | |
a
Notes: HIV vaccine numbers assigned in order of decreasing acceptability, not order of presentation to participants.
b
Mean impact score reflects the impact of each vaccine attribute on acceptability.
*
p < .05 for the one-sample two-tailed t-test.